5 Star

NASHVILLE -- Among multiple sclerosis (MS) patients experiencing breakthrough disease on standard-dose once-a-week interferon beta 1-a (IFN-1α), switching to twice-weekly dosing may offer advantages, a researcher reported here.

More than half of patients with breakthrough disease and adequate follow-up (26/52 patients) who were switched to twice-weekly treatment had no further clinical relapses, new T2 lesions, or enhanced lesions on MRI, or worsening of Expanded Disability Status Scale (EDSS) during at least 14 months (range 14 to 192 months) of follow-up, according to Robert Baumhefner, MD, of the VA Greater Los Angeles Healthcare System.

.
. .
.
.
.
.
http://game-rapidshare.com/Branter-daughter-of-Rockers-from-Duque-De-Caxias?Requadaug=280
.
. .
.
.
Pioneering keyhole procedure that seals leaking heart valves   People left breathless and even housebound by a common heart condition can now benefit from a pioneering keyhole procedure that spares them the ordeal of open surgery
.
.
.